Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry

Synapse

Volumn 69, Issue 3, 2015, Pages 103-114

  Muñoz Arenas, Guadalupe ^a   Paz Bermúdez, Francisco ^b   Báez Cordero, Ana ^a   Caballero Florán, René ^b   González Hernández, Brenda ^c   Florán, Benjamín ^b   Daniel Limon I ^a  

^a BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Cannabinoid CB1 receptor; Dopaminergic D2 receptor; GABA release; GABA uptake; Globus pallidus; Motor asymmetry

Indexed keywords

4 AMINOBUTYRIC ACID; CANNABINOID 1 RECEPTOR; DOPAMINE; DOPAMINE 2 RECEPTOR; METHAMPHETAMINE; QUINPIROLE; 4 AMINOBUTYRIC ACID RECEPTOR; ARACHIDONIC ACID DERIVATIVE; ARACHIDONYL-2-CHLOROETHYLAMIDE; OXIDOPAMINE;

4 AMINOBUTYRIC ACID RELEASE; 4 AMINOBUTYRIC ACID UPTAKE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENERVATION; GABAERGIC TRANSMISSION; GLOBUS PALLIDUS; LOCOMOTION; MALE; MICROINJECTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; AGONISTS; ANIMAL; DRUG EFFECTS; METABOLISM; MOVEMENT (PHYSIOLOGY); PHYSIOLOGY; SYNAPTIC TRANSMISSION; WISTAR RAT;

ANIMALS; ARACHIDONIC ACIDS; GABAERGIC NEURONS; GAMMA-AMINOBUTYRIC ACID; GLOBUS PALLIDUS; MALE; METHAMPHETAMINE; MOVEMENT; OXIDOPAMINE; QUINPIROLE; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTORS, DOPAMINE D2; SYNAPTIC TRANSMISSION;

EID: 84921344514     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21796     Document Type: Article

References (51)

1. Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. 1997 Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]raclopride. Mov Disord 12:33-38.
2. Blum D, Torch S, Lambeng N, Nissou MF, Benabid AL, Sadoul R, Verna JM. 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson's disease. Progr Neurobiol 65:135-172.
3. Chaves-Kirsten GP, Mazucanti CH, Real CC, Souza BM, Britto LR, Torrão AS. 2013. Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats. PLoS One 8:1-15.
4. Cui G, Jun SB, Jin X, Pham MD, Vogel SS, Lovinger DM, Costa RM. 2013. Concurrent activation of striatal direct and indirect pathways during action initiation. Nature 494:238-245.
5. Deumens R, Blokland A, Prickaerts J. 2002. Modeling Parkinson's disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303-317.
6. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. 2000. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14:1432-1438.
7. El Banoua F, Caraballo I, Flores Juan A, Galan-Rodríguez B, Fernandez-Espejo E. 2004. Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model. Neurobiol Dis 16:377-385.
8. 1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesión in experimental parkinsonism. Neurobiol Dis 18:591-601.
9. Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A. 2003. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci 18:1607-1614.
10. Floran B, Aceves J, Sierra A, Martinez-Fong D. 1990. Activation of D1 dopamine receptors stimulates the release of GABA in the basal ganglia of the rat. Neurosci Lett 116:136-140.
11. 2 receptor-mediated inhibition of GABA release by endogenous dopamine in the rat globus pallidus. Neurosci Lett 237:1-4.
12. Floran B, Floran L, Erlij D, Aceves J. 2004. Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus. Eur J Pharmacol 498:97-102.
13. Fox SH, Henry B, Hill M, Crossman A, Brotchie J. 2002. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 17:1180-1187.
14. Galvan A, Wichmann T. 2008. Pathophysiology of Parkinsonism. Clin Neurophysiol 119:1459-1474.
15. Galvan A, Villalba RM, West SM, Maidment NT, Ackerson LC, Smith Y, Wichmann T. 2005. GABAergic modulation of the activity of globus pallidus neurons in primates: In vivo analysis of the functions of GABA receptors and GABA transporters. J Neurophysiol 94:990-1000.
16. Galvan A, Hu X, Smith Y, Wichmann T. 2010. Localization and function of GABA transporters in the globus pallidus of parkinsonian monkeys. Exp Neurol 223:505-515.
17. 3H]GABA release from depolarization stimulated slices of rat substantia Nigra pars reticulate. Neurosci 80:241-249.
18. Gerfen CR, Surmeier DJ. 2011. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 34:441-466.
19. 2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. J Neurosci 17:5327-5333.
20. González-Aparicio R, Moratalla R. 2014. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson's disease. Neurobiol Dis 62:416-425.
21. 1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res 1073:209-219.
22. Gonzalez B, Paz F, Florán L, Aceves J, Erlij D, Florán B. 2006. Adenosine A2A receptor stimulation decreases GAT-1 mediated GABA uptake in the globus pallidus of the rat. Neuropharmacology 51:154-159.
23. 2 receptors. J Pharmacol Exp Ther 328:822-828.
24. Herkenham M, Lynn AB, De Costa BR, Richfield EK. 1991. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547:267-274.
25. Howlett AC. 1998. The CB1 cannabinoid receptor in the Brain. Neurobiol Dis 5:405-416.
26. Hudson JL, Van Horne CG, Stromberg I, Brock S, Clayton J, Masserano J, Hoffer BJ, Gerhardt GA. 1993. Correlation of apomorphine- and amphetamine- induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 626:167-174.
27. Jarrahian A, Watts VJ, Barker EL. 2004. D2 dopamine receptors modulate Gα-subunit coupling of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 308:880-886.
28. Julian MD, Martin AB, Cuellar B, Rodríguez de Fonseca F, Navarro M. Moratalla R. García-Segura LM. 2003. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 119:309-318.
29. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M. 2005. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: A mechanism for receptor cross-talk? Mol Pharmacol 67:1697-1704.
30. 1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. Behav Brain Res 203:304-307.
31. Khan SS, Lee FJ. 2013. Delineation of domains within the cannabinoid CB1 and dopamine D2 receptors that mediate the formation of the heterodimer complex. J Mol Neurosci 53:10-21.
32. Kita H, Kita T. 2011. Role of striatum in the pause and burst generation in the globus pallidus of 6-OHDA-treated rats. Front Syst Neurosci 5:1-11.
33. Köfalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, Sperlagh B. 2005. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: A combined immunochemical and pharmacological analysis. J Neurosci 25:2874-2884.
34. 1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci 14:1827-1832.
35. Maneuf YP, Brotchie JM. 1997. Paradoxical action of the cannabinoid WIN 55, 212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 120:1397-1398.
36. 9-tetrahidrocanabinol reduces γ-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 308:161-164.
37. Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I, Tanganelli S, Müller CE, Fisone G, Lluis C, Agnati LF, Franco R, Fuxe K. 2008. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 54:815-823.
38. Martín AB, Fernandez-Espejo E, Ferrer B, Gorriti MA, Bilbao A, Navarro M, Rodriguez de Fonseca F, Moratalla R. 2008. Expression and function of CB1 receptor in the rat striatum: Localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 33:1667-1679.
39. Morgese MG, Cassano T, Cuomo V, Giuffrida A. 2007. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp Neurol 208:110-119.
40. Myers RD. 1966. Injection of solutions into cerebral tissue: Relation between volume and diffusion. Physiol and Behav 1:171-174.
41. Obeso JA, Lanciego JL. 2011. Past, present, and future of the pathophysiological model of the basal ganglia. Front Neuroanat 5:1-6.
42. Oorschot DE. 1996. Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basalganglia: A stereological study using the cavalieri and optical disector methods. J Comp Neurol 366:580-599.
43. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates, 4th ed. San Diego, California: Academic Press.
44. 3H]-cAMP production in substantia nigra pars reticulata of the rat. Neuropharmacology 55:704-711.
45. Romero J, De Miguel R, Ramos JA, Fernández-Ruiz JJ. 1998 The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. Life Sci 62:351-363.
46. Romero J, Berrendero F, Pérez-Rosado A, Manzanares J, Rojo A, Fernández-Ruiz JJ, de Yebenes JG, Ramos JA. 2000. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci 66:485-494.
47. Salvi R, Arsenijevic Y, Giacomini M, Rey JP, Voirol MJ, Gaillard RF, Risold PY, Pralong F. 2009. The fetal hypothalamus has the potential to generate cells with a gonadotropin releasing hormone (GnRH) phenotype. PLoS One 4:1-9.
48. Sañudo-Peña MC, Walker JM. 1998. Effects of intrapallidal cannabinoids on rotational behavior in rats: Interactions with the dopaminergic system. Synapse 28:27-32.
49. Sañudo-Peña MC, Patrick SL, Khen S, Patrick RL, Tsou K, Walker JM. 1998. Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci Lett 248:171-174.
50. Souilhac J, Poncelet M, Rinaldi-Carmona M, Le Fur G, Soubrié P. 1995. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol Biochem Behav 51:3-7.
51. Sullivan AM, Opacka-Juffry J, Blunt SB. 1998. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur J Neurosci 10:57-63.